| Use of the intestinal bile acid transporter for the uptake of cholic acid conjugates with HIV-1 protease inhibitory activity M Kågedahl, PW Swaan, CT Redemann, M Tang, CS Craik, FC Szoka, ... Pharmaceutical research 14, 176-180, 1997 | 64 | 1997 |
| A positron emission tomography study in healthy volunteers to estimate mGluR5 receptor occupancy of AZD2066—estimating occupancy in the absence of a reference region M Kågedal, Z Cselényi, S Nyberg, P Raboisson, L Ståhle, P Stenkrona, ... Neuroimage 82, 160-169, 2013 | 55 | 2013 |
| Modelling a spontaneously reported side effect by use of a Markov mixed-effects model PH Zingmark, M Kågedal, MO Karlsson Journal of pharmacokinetics and pharmacodynamics 32, 261-281, 2005 | 53 | 2005 |
| Model‐informed therapeutic dose optimization strategies for antibody–drug conjugates in oncology: what can we learn from US Food and Drug Administration–approved antibody–drug … MZ Liao, D Lu, M Kågedal, D Miles, D Samineni, SN Liu, C Li Clinical Pharmacology & Therapeutics 110 (5), 1216-1230, 2021 | 51 | 2021 |
| Time‐to‐event analysis of polatuzumab vedotin‐induced peripheral neuropathy to assist in the comparison of clinical dosing regimens D Lu, WR Gillespie, S Girish, P Agarwal, C Li, J Hirata, YW Chu, ... CPT: pharmacometrics & systems pharmacology 6 (6), 401-408, 2017 | 43 | 2017 |
| Development of a subcutaneous fixed‐dose combination of pertuzumab and trastuzumab: results from the phase Ib dose‐finding study WP Kirschbrown, C Wynne, M Kågedal, R Wada, H Li, B Wang, I Nijem, ... The Journal of Clinical Pharmacology 59 (5), 702-716, 2019 | 42 | 2019 |
| Blood–brain barrier penetration of zolmitriptan—modelling of positron emission tomography data M Bergström, R Yates, A Wall, M Kågedal, S Syvänen, B Långström Journal of Pharmacokinetics and Pharmacodynamics 33, 75-91, 2006 | 42 | 2006 |
| Norepinephrine transporter occupancy in the human brain after oral administration of quetiapine XR S Nyberg, A Jucaite, A Takano, M Kågedal, Z Cselényi, C Halldin, L Farde International Journal of Neuropsychopharmacology 16 (10), 2235-2244, 2013 | 37 | 2013 |
| Non-linear mixed effects modelling of positron emission tomography data for simultaneous estimation of radioligand kinetics and occupancy in healthy volunteers M Kågedal, Z Cselényi, S Nyberg, S Jönsson, P Raboisson, P Stenkrona, ... NeuroImage 61 (4), 849-856, 2012 | 32 | 2012 |
| Distribution of zolmitriptan into the CNS in healthy volunteers: a positron emission tomography study A Wall, M Kågedal, M Bergström, E Jacobsson, D Nilsson, G Antoni, ... Drugs in R & D 6, 139-147, 2005 | 32 | 2005 |
| Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology S Kawakatsu, R Bruno, M Kågedal, C Li, S Girish, A Joshi, B Wu British Journal of Clinical Pharmacology 87 (6), 2493-2501, 2021 | 30 | 2021 |
| Dose-dependent binding of AZD3783 to brain 5-HT1B receptors in non-human primates and human subjects: a positron emission tomography study with [11C … K Varnäs, S Nyberg, P Karlsson, ME Pierson, M Kågedal, Z Cselényi, ... Psychopharmacology 213, 533-545, 2011 | 30 | 2011 |
| True nasopharyngeal absorption of zolmitriptan after administration via nasal spray in healthy male volunteers M Kågedal, PH Zingmark, C Hedlund, R Yates American Journal of Drug Delivery 3, 133-140, 2005 | 23* | 2005 |
| PET-measured occupancy of the norepinephrene transporter by extended release quetiapine fumarate (quetiapine XR) in brains of healthy subjects S Nyberg, A Takano, A Jucaite, P Karlsson, D McCarthy, M Kagedal, ... European Neuropsychopharmacology 18, S270-S270, 2008 | 20 | 2008 |
| Support to early clinical decisions in drug development and personalised medicine with checkpoint inhibitors using dynamic biomarker-overall survival models R Bruno, P Chanu, M Kågedal, F Mercier, K Yoshida, J Guedj, C Li, ... British journal of cancer 129 (9), 1383-1388, 2023 | 18 | 2023 |
| Intrinsic and extrinsic pharmacokinetic variability of small molecule targeted cancer therapy E Reyner, B Lum, J Jing, M Kagedal, JA Ware, LJ Dickmann Clinical and Translational Science 13 (2), 410-418, 2020 | 18 | 2020 |
| Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC) SC Chen, M Kagedal, Y Gao, B Wang, ML Harle-Yge, S Girish, J Jin, C Li Cancer Chemotherapy and Pharmacology 80, 1147-1159, 2017 | 18 | 2017 |
| Evaluation of the effects of a metabotropic glutamate receptor 5‐antagonist on electrically induced pain and central sensitization in healthy human volunteers J Kalliomäki, K Huizar, M Kågedal, B Hägglöf, M Schmelz European Journal of Pain 17 (10), 1465-1471, 2013 | 18 | 2013 |
| A study of organic acid transporter-mediated pharmacokinetic interaction between NXY-059 and cefuroxime. M Kågedal, D Nilsson, G Huledal, I Reinholdsson, CYF Cheng YiFang, ... | 17 | 2007 |
| A new method to model and predict progression free survival based on tumor growth dynamics J Yu, N Wang, M Kågedal CPT: pharmacometrics & systems pharmacology 9 (3), 177-184, 2020 | 16 | 2020 |
Andrew C. HookerProfessor of Pharmacometrics, Uppsala UniversityVerifierad e-postadress på farmaci.uu.se